Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Top Cited Papers
- 1 January 2012
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 130 (1), 9-24
- https://doi.org/10.1001/archophthalmol.2011.298
Abstract
To determine safety and efficacy of subretinal gene therapy in the RPE65 form of Leber congenital amaurosis using recombinant adeno-associated virus 2 (rAAV2) carrying human RPE65 gene. Open-label, dose-escalation Phase I study of 15 patients (11-30 years) evaluated after subretinal injection of rAAV2-hRPE65 to the worse-functioning eye. Five cohorts represented four dose levels and two different injection strategies. Primary outcomes were systemic and ocular safety. Secondary outcomes assayed visual function with dark-adapted full-field sensitivity testing and ETDRS visual acuity. Further assays included immune responses to the vector, static visual fields, pupillometry, mobility performance and OCT. No systemic toxicity was detected; ocular adverse events were related to surgery. Visual function improved in all patients to different degrees; improvements were localized to treated areas. Cone and rod sensitivities increased significantly in study eyes but not control eyes. Minor acuity improvements were recorded in many study and control eyes. Major acuity improvements occurred in study eyes with the lowest entry acuities and parafoveal fixation loci treated with subretinal injections. Other patients with better foveal structure lost retinal thickness and acuity after subfoveal injections. RPE65-LCA gene therapy is sufficiently safe and substantially efficacious to the extrafoveal retina. There is no benefit and some risk in treating the fovea. No evidence of age-dependent effects was found. Our results point to specific treatment strategies for subsequent phases. Gene therapy for inherited retinal disease has the potential to become a future part of clinical practice.Keywords
This publication has 52 references indexed in Scilit:
- Advantages and Limitations of Small Gauge VitrectomySurvey of Ophthalmology, 2011
- The Cone-specific visual cycleProgress in Retinal and Eye Research, 2011
- Retinal Disease in Rpe65-Deficient Mice: Comparison to Human Leber Congenital Amaurosis Due toRPE65MutationsInvestigative Ophthalmology & Visual Science, 2010
- Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationMolecular Therapy, 2010
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialThe Lancet, 2009
- Defining the Residual Vision in Leber Congenital Amaurosis Caused byRPE65MutationsInvestigative Ophthalmology & Visual Science, 2009
- Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis.2007
- Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).2005
- Laser flare-cell photometry: methodology and clinical applicationsSurvey of Ophthalmology, 2005
- Identification of the RPE65 protein in mammalian cone photoreceptors.2002